Selumetinib sulfateProduct ingredient for Selumetinib

Activation of the Raf-MEK-ERK signalling pathway is known to be implemented in several types of malignancies; thus, mitogen-activated protein kinase kinase (MEK) inhibitors such as selumetinib are important tools that can target the problematic overactivity of this pathway.⁶ Results from clinical trials investigating earlier developed MEK inhibitors were underwhelming.⁶ However, selumetinib demonstrated impressive efficacy and tolerability in Phase I trials, leading to its continued investigation for the treatment of various types of tumours in Phase II trials.⁶

"The novel MEK 1/2 inhibitor, selumetinib, was initially approved solely for the treatment of pediatric patients with Neurofibromatosis type 1 (NF-1) and symptomatic, inoperable plexiform neurofibromas (PN). NF-1 is considered rare, with an estimated incidence of 1/3000 individuals.⁵ It is a genetic, autosomal dominant condition resulting from mutations of the NF1 gene, which can lead to various complications, including the development of multiple tumours in the nervous system.^3,5 While some patients with this disorder develop PNs, this is considered relatively uncommon compared to other variants of NF-1.⁵ Use of selumetinib in this population has shown efficacy in shrinking associated tumours and is linked to other positive clinical outcomes.³ Following its initial FDA approval on April 10, 2020,¹⁶ and Health Canada approval on August 23, 2022,¹⁵ the regulatory landscape has evolved. Most recently, on November 20, 2025, the FDA expanded this indication to include adults ¹⁷